GSK

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Nuclear medicine #Oncology #Osteosarcoma #UK government

This week in Drug Discovery (17 – 21 November) 

News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW.  This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer.  The top stories:    Medication detrimental to gut microbiome,… Read More

#News

Human liver
#Genomics #GSK #Liver disease #Ochre Bio

Ochre Bio and GSK complete early research into human liver 

Biotechnology company Ochre Bio has completed research into human liver functional genomics and single-cell datasets, following a partnership with GSK.  Results include a large-scale functional genomics data from research into primary human hepatocytes and a single-cell dataset built from perfused human donor livers.  Ochre’s research… Read More

#News

Cancer cells
#Cancer research #GSK #Immuno-oncology

GSK partners with LTZ to develop myeloid cell engagers 

GSK has announced a strategic collaboration with biotechnology company LTZ to advance novel myeloid cell engagers (MCEs) in oncology.   The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumours. The agreement grants GSK an exclusive option to license worldwide development… Read More

#Business & Investment #News

Bacteria in Petri dishes
#Antimicrobial resistance (AMR) #Gram-negative bacteria #GSK

GSK and Fleming Initiative launch programmes to tackle AMR 

GSK and the Fleming Initiative have launched six major new research programmes aiming to combat antimicrobial resistance (AMR).  The six ‘Grand Challenges’ will bring together scientific expertise and the latest technologies, including AI, to find new ways to slow the progress of AMR. The project has been backed by… Read More

#News

GSK offices
#Antibody drug conjugate (ADC) #Cancer research #GSK

GSK buys rights to develop ADC treatment for prostate cancer 

GSK has acquired exclusive rights from biotechnology company Syndivia to develop and commercialise an antibody-drug conjugate (ADC) in prostate cancer.  The global biopharma company aims to develop the ADC for metastatic castration-resistant prostate cancer (mCRPC), which remains a significant health burden for men.  Approximately 1.4… Read More

#Business & Investment #News

#GSK #Investment #Manufacturing

GSK to invest $30 billion in US over next five years

GSK will invest $30 billion (£22 billion) across the US over the next five years in research and development and supply chain infrastructure, the company has announced.  The investment includes a new $1.2 billion (£880 million) investment in advanced manufacturing facilities and AI and advanced digital technologies,… Read More

#Business & Investment #News

Older adult receiving vaccine
#Dementia #GSK #Immunology / Virology & Vaccines #Neuroscience #Shingles

RWD shows shingles vaccine reduces dementia risk

GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.  Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More

#News #Trending News

Multiple myeloma
#FDA #GSK #Monoclonal antibodies #Myeloma #Oncology

FDA committee votes against Blenrep combinations for myeloma

The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile at GSK’s proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.   The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least… Read More

#News #Regulatory

Multiple myeloma
#GSK #Japan #Myeloma #Oncology

Blenrep combinations approved in Japan for multiple myeloma

Blenrep combinations have been approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma.  The approval follows an orphan drug designation for Blenrep in Japan, which was granted based on its ability to address high unmet… Read More

#News #Regulatory

Human liver
#Fibrosis #GSK #Liver disease #Mergers and acquisitions

GSK buys drug with potential to reverse liver fibrosis

GSK has announced plans to acquire efimosfermin, a Phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD).  The acquisition significantly expands GSK’s hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options and potential… Read More

#Business & Investment #News

Patient taking antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobials #Bacteria #FDA #GSK #Urinary

New class of oral antibiotics for uUTIs gets FDA green light

The US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40kg) with uncomplicated urinary tract infections (uUTIs).  It is approved to treat infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae,… Read More

#News #Regulatory

Vaccine vial and syringe
#Cancer vaccine #GSK #Immuno-oncology #Oncology #University of Oxford

Oxford and GSK launch £50m cancer vaccines programme

GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines.  The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and… Read More

#Business & Investment #Cancer Research #News

Gastrointestinal tract
#Gastrointestinal #GSK #Mergers and acquisitions #Oncology

GSK grows gastrointestinal cancers portfolio with new acquisition

GSK has revealed it will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).  Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.   The… Read More

#Business & Investment #Cancer Research #News

#Alzheimer's #Collaboration #GSK #Muna Therapeutics #Neuroscience #Transcriptomics

GSK and Muna ally on novel treatments for Alzheimer’s disease

GSK and biotechnology company Muna Therapeutics have entered a research alliance to identify and validate novel drug targets for the treatment of Alzheimer’s disease.   The companies will explore insights from Muna’s MiND-MAP platform, which applies spatial transcriptomics to brain samples from Alzheimer’s disease patients, cognitively resilient individuals,… Read More

#Business & Investment #News

Lungs
#Autoimmune disease #Clinical trial #GSK #Interview #Lung disease

GSK’s autoimmune efforts

DDW Editor Reece Armstrong speaks to Roger Levy, Global Medical Expert Immunology & Specialty Medicine at GSK about the company’s work into treating systemic sclerosis-associated interstitial lung disease and its recent BLISSc-ILD study evaluating its belimumab treatment.  RA: Can you give us an overview of the BLISSc-ILD study? RL:… Read More

#Exclusive Content

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #GSK #Phase III trial

GSK announces positive data for gonorrhoea antibiotic

Positive results have been announced by GSK for its antibiotic targeting uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the… Read More

#Editor's Choice #News